- 1 SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations
- 2 Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic
- 3 Infection
- 4 Amy J. Schuh¹, Panayampalli S. Satheshkumar¹, Stephanie Dietz¹, Lara Bull-Otterson¹, Myrna Charles¹,
- 5 Chris Edens¹, Jefferson M. Jones¹, Kristina L. Bajema¹, Kristie E.N. Clarke¹, L. Clifford McDonald¹,
- 6 Sadhna Patel¹, Kendra Cuffe¹, Natalie J. Thornburg¹, Jarad Schiffer¹, Kelly Chun², Monique Bastidas²,
- 7 Manory Fernando², Christos J. Petropoulos², Terri Wrin², Suqin Cai², Dot Adcock², Deborah Sesok-
- 8 Pizzini², Stanley Letovsky², Alicia M. Fry¹, Aron J. Hall¹, Adi V. Gundlapalli¹
- 9 ¹CDC COVID-19 Response, United States Centers for Disease Control and Prevention, Atlanta, GA
- 10 ²Labcorp, Burlington, NC
- 11 Running title: Convalescent sera antibody levels compared to vaccine efficacy estimates
- 12 Abstract word count: 172
- 13 Text word count: 3,282

14 **Footnotes**

- ¹⁵ ¹Potential conflicts of interest have been disclosed within the ICMJE Disclosure Forms.
- ¹⁶ ²This work was supported by the United States Centers for Disease Control and Prevention.
- ³This work has not been presented at any national or international meeting.
- ⁴Correspondence: Adi V. Gundlapalli, MD, PhD, Center for Surveillance, Epidemiology, and
- 19 Laboratory Services, United States Centers for Disease Control and Prevention, Atlanta, Georgia,
- 20 30333; agundlapalli@cdc.gov

21 ABSTRACT

22	Previous vaccine efficacy (VE) studies have estimated neutralizing and binding antibody
23	concentrations that correlate with protection from symptomatic infection; how these estimates compare
24	to those generated in response to SARS-CoV-2 infection is unclear. Here, we assessed quantitative
25	neutralizing and binding antibody concentrations using standardized SARS-CoV-2 assays on 3,067
26	serum specimens collected during July 27, 2020-August 27, 2020 from COVID-19 unvaccinated persons
27	with detectable anti-SARS-CoV-2 antibodies using qualitative antibody assays. Quantitative neutralizing
28	and binding antibody concentrations were strongly positively correlated (r=0.76, p<0.0001) and were
29	noted to be several fold lower in the unvaccinated study population as compared to published data on
30	concentrations noted 28 days post-vaccination. In this convenience sample, ~88% of neutralizing and
31	~63-86% of binding antibody concentrations met or exceeded concentrations associated with 70%
32	COVID-19 VE against symptomatic infection from published VE studies; ~30% of neutralizing and 1-
33	14% of binding antibody concentrations met or exceeded concentrations associated with 90% COVID-
34	19 VE. These data support observations of infection-induced immunity and current recommendations
35	for vaccination post infection to maximize protection against symptomatic COVID-19.
36	
37	Keywords: SARS-CoV-2, COVID-19, quantitative anti-SARS-CoV-2 IgG, neutralizing antibodies,

38 correlation, antibody, immune, protection, correlate of protection

39 BACKGROUND

41vaccinated for COVID-19 [1]. A recent Gallup survey found that 18% of Americans would not agree to42be vaccinated if a US Food and Drug Administration (FDA)-approved COVID-19 vaccine were43available to them immediately at no cost [2]. One of the primary reasons cited for vaccine hesitancy was44a history of SARS-CoV-2 infection and resultant antibodies.45Cumulative evidence indicates that SARS-CoV-2 antibodies are protective against SARS-CoV-2 re-46infection [3]. A series of non-human primate challenge studies demonstrated the central role of SARS-47CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial48involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-249neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated50that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A51longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced52protective immunity lasts for at least 6 months [8].53The establishment of the First World Health Organization (WHO) International Standard for Anti-54SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody55concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and56symptomatic infection) in fully-vaccinated persons (i.c., 2 weeks after their second dose in a 2-dose58series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOX1)	40	As of October 18, 2021, 66.7% of the US population 12 years of age and older has been fully
 available to them immediately at no cost [2]. One of the primary reasons cited for vaccine hesitancy was a history of SARS-CoV-2 infection and resultant antibodies. Cumulative evidence indicates that SARS-CoV-2 antibodies are protective against SARS-CoV-2 re- infection [3]. A series of non-human primate challenge studies demonstrated the central role of SARS- CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	41	vaccinated for COVID-19 [1]. A recent Gallup survey found that 18% of Americans would not agree to
 a history of SARS-CoV-2 infection and resultant antibodies. Cumulative evidence indicates that SARS-CoV-2 antibodies are protective against SARS-CoV-2 re- infection [3]. A series of non-human primate challenge studies demonstrated the central role of SARS- CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	42	be vaccinated if a US Food and Drug Administration (FDA)-approved COVID-19 vaccine were
 Cumulative evidence indicates that SARS-CoV-2 antibodies are protective against SARS-CoV-2 re- infection [3]. A series of non-human primate challenge studies demonstrated the central role of SARS- CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	43	available to them immediately at no cost [2]. One of the primary reasons cited for vaccine hesitancy was
 infection [3]. A series of non-human primate challenge studies demonstrated the central role of SARS- CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	44	a history of SARS-CoV-2 infection and resultant antibodies.
 CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	45	Cumulative evidence indicates that SARS-CoV-2 antibodies are protective against SARS-CoV-2 re-
 involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	46	infection [3]. A series of non-human primate challenge studies demonstrated the central role of SARS-
 neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	47	CoV-2 neutralizing antibodies in protection from re-infection [4-6]. A randomized clinical trial
 that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	48	involving the subcutaneous administration of REGEN-COV, a combination of two SARS-CoV-2
 longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	49	neutralizing monoclonal antibodies, or placebo within 96 hours of SARS-CoV-2 exposure demonstrated
 protective immunity lasts for at least 6 months [8]. The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	50	that REGEN-COV prevented symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection [7]. A
The establishment of the First World Health Organization (WHO) International Standard for Anti- SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody	51	longitudinal study of >12,000 health care workers showed that SARS-CoV-2 infection-induced
 SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	52	protective immunity lasts for at least 6 months [8].
 concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	53	The establishment of the First World Health Organization (WHO) International Standard for Anti-
 propose standardized immune correlates of protection against symptomatic infection (or risk of symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	54	SARS-CoV-2 Immunoglobulin [9] for quantitative assessment of neutralizing and binding antibody
 symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	55	concentrations has made it possible for COVID-19 vaccine efficacy (VE) studies [10-13] to describe and
 series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1) vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	56	propose standardized immune correlates of protection against symptomatic infection (or risk of
 vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735] vaccine) across vaccine trials that have used different antibody assays. Comparing antibody 	57	symptomatic infection) in fully-vaccinated persons (i.e., 2 weeks after their second dose in a 2-dose
60 vaccine) across vaccine trials that have used different antibody assays. Comparing antibody	58	series, such as Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), or AstraZeneca (ChAdOx1)
	59	vaccines OR 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen [JNJ-78436735]
61 concentrations of unvaccinated persons with anti-SARS-CoV-2 antibodies to COVID-19 vaccinated	60	vaccine) across vaccine trials that have used different antibody assays. Comparing antibody
	61	concentrations of unvaccinated persons with anti-SARS-CoV-2 antibodies to COVID-19 vaccinated
62 cohorts and to estimated antibody concentrations associated with COVID-19 vaccine effectiveness	62	cohorts and to estimated antibody concentrations associated with COVID-19 vaccine effectiveness

63 would accomplish three goals: 1) improve understanding of the population distribution of antibody 64 concentrations in response to infection and vaccination. 2) help establish relationship of quantitative 65 antibody levels to those associated with protection against illness from published studies, and 3) inform 66 better targeted messaging for universal COVID-19 vaccination. 67 Numerous SARS-CoV-2 serological assays have been developed over the course of the COVID-19 68 pandemic to measure virus-specific antibody responses [14]. Persons who recover from SARS-CoV-2 69 infection or receive a COVID-19 vaccine typically develop virus-specific neutralizing antibodies, with 70 most of these antibodies directed against the immunodominant receptor binding domain (RBD) of the 71 spike (S) protein [15, 16]. Efficacy trials of the ChAdOx1 [11] and mRNA-1273 [12] vaccines showed 72 that higher anti-SARS-CoV-2 S IgG, anti-SARS-CoV-2 RBD IgG, and SARS-CoV-2 neutralizing 73 antibody concentrations were correlated with a reduced risk of symptomatic infection. Both trials 74 determined antibody concentrations associated with varying levels of VE against symptomatic COVID-75 19 [11, 12]. The ChAdOx1 vaccine trial estimated that 70% and 90% VE against symptomatic COVID-76 19 was associated with 50% neutralizing antibody titer (NT_{50}) concentrations of 3.7 and 64.1 77 international units per mL (IU/mL), respectively, and 70% and 90% VE was associated with anti-RBD 78 IgG antibodies concentrations of 165.0 and 2360.0 binding antibody units per mL (BAU/mL), 79 respectively [11]. The mRNA-1273 vaccine trial estimated that 70% and 90% VE against symptomatic 80 COVID-19 was associated with NT₅₀ concentrations of 4.0 and 83.0 IU/mL, respectively, and 70% and 81 90% VE was associated with anti-RBD IgG antibodies concentrations of 8.0 and 775.0 BAU/mL, 82 respectively [12]. However, it remains unclear how these antibody concentrations compare to those 83 generated in response to SARS-CoV-2 infection in COVID-19 unvaccinated persons. To answer this 84 question, we tested 3,067 pre-vaccination sera collected as part of a nationwide commercial laboratory 85 seroprevalence study led by the US Centers for Disease Control and Prevention (CDC) [17] that had 86 previously tested positive for anti-SARS-CoV-2 antibodies using standardized anti-SARS-CoV-2 RBD

IgG and SARS-CoV-2 pseudovirus neutralization antibody assays, and then compared these antibody concentrations to concentrations measured in COVID-19 vaccinated cohorts (28 days post-vaccination) and to those associated with 70% and 90% COVID-19 VE against symptomatic infection for two of the vaccines for which such data are published to date.

91 **METHODS**

92 Specimen Source and Study Design

93 Sera were collected by two US-based commercial laboratories for routine or acute clinical care (e.g., 94 cholesterol screening or a sick visit) as part of a nationwide scroprevalence study; detailed methods have 95 previously been described [17]. Briefly, blood specimens collected for COVID-19-related reasons were 96 excluded. Sera were tested [17] for anti-SARS-CoV-2 antibodies using one of the following three 97 qualitative assays issued emergency use authorization by the FDA that were in use in the clinical laboratories: 1) ArchitectTM SARS-CoV-2 IgG Assay (nucleocapsid (N) protein; Abbott, Chicago, IL), 98 99 2) VITROS® Anti-SARS-CoV-2 IgG Assay (S protein; Ortho-Clinical Diagnostics, Raritan, NJ), and 3) 100 Elecsys® Anti-SARS-CoV-2 Assay (N protein; Roche, Indianapolis, IN) (Supplementary figure 3). 101 Among 84,683 total serum samples collected during July 27, 2020-August 27, 2020 identified as anti-102 SARS-CoV-2 antibody positive and had linked age and sex information (as part of the larger 103 serosurveillance study) [17], 3067 serum specimens were selected by convenience sampling for reflex 104 testing with anti-SARS-CoV-2 quantitative IgG and neutralizing antibody assays. Data on race, 105 ethnicity, and occurrence or date of SARS-CoV-2 infection or symptoms were not available; data on 106 prior SARS-CoV-2 quantitative reverse transcription polymerase chain reaction qRT-PCR test results 107 were not available for most persons.

108 Ethics

109 This activity was reviewed by CDC and was conducted consistent with applicable federal law and 110 CDC policy (45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 111 U.S.C. Sect. 3501 et seq.). Informed consent was waived, as all data were deidentified. 112 PhenoSense[®] CoV Neutralizing Antibody Assay 113 Neutralizing antibodies against the SARS-CoV-2 S protein were measured using the PhenoSense 114 CoV Neutralizing Antibody Assay® [18]. To measure SARS-CoV-2 neutralizing antibodies, human 115 immunodeficiency virus-1 pseudovirions expressing the SARS-CoV-2 S protein were prepared by co-116 transfecting HEK293 producer cells with an HIV-1 genomic vector and a SARS-CoV-2 envelope 117 protein expression vector. Serial dilutions of sera were incubated with recombinant pseudovirions and neutralizing activity was assessed by measuring the inhibition of luciferase activity in HEK293 target 118 119 cells co-expressing the angiotensin-converting enzyme 2 and transmembrane serine protease 2 receptors. 120 Fifty percent neutralizing antibody titers (NT₅₀) were expressed as the reciprocal of the serum dilution 121 conferring 50% inhibition of pseudovirus infection. Calibration of the PhenoSense CoV Neutralizing 122 Antibody Assay® with the First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin 123 (20/136, National Institute for Biological Standards and Controls, UK) [9] allowed us to generate a 124 calibration factor of 0.0653 (S protein containing G614) and convert NT₅₀ values from titers to 125 international units per mL (IU/mL) by multiplying by the calibration factor. 126 **Cov2Ouant IgG® Assav**

127 Anti-SARS-CoV-2 RBD IgG in sera were quantified using the electrochemiluminescent (ECL)

128 Cov2Quant IgG® Assay [19]. Briefly, sera were incubated with biotin-conjugated, recombinant SARS-

129 CoV-2 RBD antigen bound to a streptavidin, carbon-coated microtiter well plate. After washing the

130 plate, the wells were incubated with ruthenium-conjugated anti-IgG and a final wash was performed to

131 remove unbound material. Voltage was applied to the metallic electrode on the base of the plate and a

132 photomultiplier was used to measure the ECL signal generated from each well. The signal in relative 133 light units (RLU) is directly proportional to the anti-RBD IgG concentration in sera. Each assay batch 134 included a dilution series of affinity-purified human IgG standard that was used to calculate the anti-135 SARS-CoV-2 RBD IgG concentration of each serum. Calibration of the Cov2Ouant IgG® Assay with 136 the WHO International Standard allowed us to generate a calibration factor of 25 and convert anti-137 SARS-CoV-2 RBD IgG concentrations from µg/mL to binding antibody units per mL (BAU/mL) by 138 multiplying by the calibration factor. 139 Comparison of Study Antibody Data to Antibody Concentrations Associated with COVID-19 VE 140 Of the COVID-19 vaccines in use around the world currently, serological correlates of protection

141 thresholds associated with VE have been estimated for ChAdOx1 [11] and mRNA-1273 [12] using the

142 First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin. As the quantitative antibody

143 assays used in our study were calibrated to the same standard, we were able to compare antibody

144 concentrations in our study to those estimated to be associated with 70% and 90% COVID-19 VE to

145 ChAdOx1 and mRNA-1273.

146 Statistical Analyses

147 Data management tasks, and statistical analyses were performed using SAS version 9.4 (SAS 148 Institute Inc., Cary, NC) and GraphPad Prism 9.0.0 (GraphPad Software, San Diego, CA). T-tests on 149 log₁₀-transformed data were used to determine if there were statistically significant differences between 150 geometric mean anti-SARS-CoV-2 RBD IgG and NT50 concentrations by sex. ANOVAs on log10-151 transformed data were used to determine if there were statistically significant differences between 152 geometric mean anti-SARS-CoV-2 RBD IgG and NT₅₀ concentration according to previous qualitative 153 antibody test and age category. Post-hoc Tukey's tests were performed to identify previous qualitative 154 antibody tests and age categories with significantly different anti-SARS-CoV-2 RBD IgG and NT50 155 concentrations; p-values were adjusted to account for multiple comparisons. Pearson's correlation was

used to assess the overall relationship between log10anti-RBD IgG and log10NT50 concentrations, as well
as the relationships between the two variables across sex and age category. Two-sided p-values <0.05
were considered statistically significant.

159 **RESULTS**

160 Of the overall convenience sample of 3,067 serum specimens collected during July 27, 2020-August

161 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay, 1,309 were from males

162 (42.7%) and 1,758 (57.3%) were from females, 779 (25.4%) were from persons aged <18 years, 982

163 (32.0%) were from persons aged 18–49 years, 798 (26.0%) were from persons aged 50–64 years, and

164 508 (16.6%) were from persons aged \geq 65 years.

165 Most of the serum specimens (n=2568, 83.7%) tested positive for both quantitative SARS-CoV-2

166 neutralizing antibodies and quantitative anti-SARS-CoV-2 RBD IgG; 271 sera (8.8%) tested negative

167 for both neutralizing antibodies and anti-RBD IgG, 83 sera (2.7%) tested negative for neutralizing

antibodies only, and 145 sera (4.7%) tested negative for anti-RBD IgG only. Geometric mean NT₅₀

169 concentrations differed significantly according to the qualitative antibody test type that was used to

170 screen sera for study inclusion (p<0.0001; Supplementary Figure 4A), while geometric mean anti-RBD

171 IgG concentrations did not differ significantly according to the qualitative antibody test type that was

172 used to screen sera for study inclusion (p=0.02998; Supplementary Figure 4B).

173 The overall geometric mean NT₅₀ concentration was 28.8 IU/mL (95% confidence interval (CI):

174 26.8, 31.0) and did not differ significantly according to sex (male: 30.9 IU/mL, 95% CI: 27.4, 34.8;

175 female: 27.3 IU/mL, 95% CI: 25.0, 30.0; p=0.1088) but differed significantly according to age category

176 (<18 years: 31.3 IU/mL, 95% CI: 28.4, 34.6; 18–49 years: 23.1 IU/mL, 95% CI: 20.3, 26.2; 50–64

177 years: 38.0 IU/mL, 95% CI: 32.5, 44.4; ≥65 years: 25.0 IU/mL, 95% CI: 20, 31.3; p<0.0001; Figure

178 1A). Persons aged <18 years had significantly higher NT₅₀ concentrations compared to persons aged 18–

179 49 years (p=0.0108), and persons aged 50–64 years had significantly higher NT₅₀ concentrations

180	compared to persons aged 18–49 years (p<0.0001) and persons aged \geq 65 years (p=0.0020) (Figure 1A).
181	The overall geometric mean anti-RBD IgG concentration was 162.5 BAU/mL (95% CI: 152.9, 172.7)
182	and did not differ significantly according to sex (male: 171.3 BAU/mL, 95% CI: 155.6, 188.5; female:
183	156.3 BAU/mL, 95% CI: 144.4, 169.1; p=0.1447) but did differ significantly according to age category
184	(<18 years: 218.2 BAU/mL, 95% CI: 199.2, 239.1; 18–49 years: 122.2 BAU/mL, 95% CI: 109.8, 136.1;
185	50–64 years: 189.0 BAU/mL, 95% CI: 167.2, 213.7; ≥65 years: 141.4 BAU/mL, 95% CI: 117.8, 169.8;
186	p<0.0001; Figure 1B). Like the age-associated patterns of neutralizing antibody concentrations, persons
187	aged <18 years had significantly higher anti-RBD IgG concentrations compared to persons aged 18-49
188	years (p<0.0001) and persons aged \geq 65 years (p<0.0001), and persons aged 50–64 years had
189	significantly higher anti-RBD IgG concentrations compared to persons aged 18–49 years (p<0.0001)
190	and persons aged \geq 65 years (p=0.0147) (Figure 1B).
191	We found an overall significant, strong positive correlation between NT50 concentrations and anti-
192	RBD IgG concentrations (r=0.76, p<0.0001; Figure 1A). The strength of the relationship remained
193	consistent across sex (male: r=0.76, p<0.0001; female: r=0.76, p<0.0001; Figure 1B) and increased with
194	increasing age category (<18 years: r=0.67, p<0.0001; 18–49 years: r=0.69, p<0.0001; 50–64 years:
195	r=0.79, p<0.0001; ≥65 years: r=0.88, p<0.0001; Figure 2).
196	NT ₅₀ concentrations in the overall convenience sample of 3,067 serum specimens collected during
197	July 27, 2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay were
198	2.7-fold lower and 8.6-fold lower than concentrations reported from serum specimens collected 28 days

199 post COVID-19 vaccination from ChAdOx1 [11] and mRNA-1273 [12] VE study participants classified

200 as not having COVID-19 during the follow-up period, respectively (Figures 3A and B). Likewise, anti-

201 RBD IgG concentrations in the overall convenience sample were 1.5-fold lower and 24.2-fold lower

than concentrations reported from serum specimens collected 28 days post COVID-19 vaccination from

203 ChAdOx1 and mRNA-1273 VE study participants classified as not having COVID-19 during the

204	follow-up period, respectively (Figure 3C and D). Overall, 88.3% of serum specimens in this study met
205	or exceeded the concentration of SARS-CoV-2 neutralizing antibodies associated with 70% ChAdOx1
206	and mRNA-1273 VE, while 32.9% and 27.1% of sera met or exceeded the concentration of SARS-CoV-
207	2 neutralizing antibodies associated with 90% ChAdOx1 and mRNA-1273 VE, respectively (Figure
208	1A). For binding antibodies, we found that 63.1% and 86.4% of serum specimens from this study met or
209	exceeded the concentration of anti-RBD IgG antibodies associated with 70% ChAdOx1 and mRNA-
210	1273 VE, respectively, and 1.3% and 13.6% of sera met or exceeded the concentration of anti-RBD IgG
211	antibodies associated with 90% ChAdOx1 and mRNA-1273 VE, respectively (Figure 1B). A greater
212	percentage of males and persons aged \geq 50 years met or exceeded the concentrations of SARS-CoV-2
213	neutralizing antibodies and anti-RBD Ig associated with 70% ChAdOx1 and mRNA-1273 VE than

214 females and persons aged <50 years, respectively.

215 **DISCUSSION**

216 Similar to the ChAdOx1 [11] and mRNA-1273 [12] VE trial serologic testing results reported in the 217 literature, we demonstrate a statistically significant, strong positive correlation between standardized 218 anti-SARS-CoV-2 RBD IgG and SARS-CoV-2 NT₅₀ concentrations, across all sex and age categories, 219 using sera from unvaccinated persons with previous SARS-CoV-2 infection. Based on these broad 220 correlations, our results suggest that high-throughput, quantitative anti-SARS-CoV-2 RBD IgG assays 221 can be used as surrogates for SARS-CoV-2 pseudovirus neutralization assays that are considered 222 mechanistic correlates of protection [12]. Performing high-throughput, commercially available 223 quantitative IgG assays is logistically feasible and practical on a large scale compared to performing 224 time- and resource-intensive neutralization assays. Thus, there is a continued need for FDA-approved 225 quantitative anti-SARS-CoV-2 S and RBD IgG assays in the management of the pandemic to facilitate 226 assessment of antibody concentrations associated with protection from infection and/or disease [14].

227	While our finding that most serum specimens in this study met or exceeded antibody concentrations
228	associated with 70% COVID VE estimates support the real-world observations of infection-induced
229	immunity from re-infection, it is important to note that less than 33% of sera from unvaccinated persons
230	with previous SARS-CoV-2 infection met or exceeded antibody concentrations associated with 90%
231	ChAdOx1 and mRNA-1273 vaccine efficacy. This suggests that not all persons with a history of SARS-
232	CoV-2 infection generate antibody responses of sufficient magnitude, as measured by a single, randomly
233	timed blood test, to protect them against symptomatic re-infection. In addition to the circulation of the
234	hyper-transmissible Delta variant of SARS-CoV-2, this finding may also partially explain the rise in
235	COVID-19 cases that occurred in the United States in August 2021 despite a national serosurvey in May
236	2021 showing that 83.3% of the population had SARS-CoV-2 infection- and/or vaccine-induced
237	antibodies [20]. Meanwhile, at least in the short-term (28 days), COVID-19 vaccination can provide 2.7
238	to 8.6-fold higher neutralizing antibody concentrations and 1.5 to 24.2-fold higher binding antibody
239	concentrations. Thus, our results support current guidance that all eligible persons should consider
240	COVID-19 vaccination to maximize their protection against symptomatic COVID-19 regardless of their
241	SARS-CoV-2 infection history.
242	Our sampling approach of selecting specimens identified as positive using at least one qualitative
243	anti-SARS-CoV-2 antibody assay would have selected for persons who had more severe disease and
244	thus higher antibody concentrations, and/or in whom antibodies had not waned. This selection bias may
245	have led us to overestimate the percentage of persons with antibody concentrations meeting or
246	exceeding those concentrations associated with 70% and 90% COVID-19 VE and would have missed
247	persons infected with SARS-CoV-2 who did not mount a measurable post-infection immune response or
248	had antibodies below detectable levels.

Our study has several limitations. First, due to the absence of information on whether persons had symptoms or if testing had been done or, if so, the date of COVID-19 symptom onset and/or a positive

251 SARS-CoV-2 qRT-PCR or antigen test, we were unable to calculate the number of days that had elapsed 252 between infection and collection of serum for antibody testing and thus the measurements might not 253 reflect peak antibody concentrations. The ChAdOx1 and mRNA-1273 VE trials measured serum 254 antibody concentrations 28 days after the second vaccine dose, presumably at the peak of the measurable 255 humoral immune response to the vaccine. Therefore, if the sera used in this study were collected >28 256 days after SARS-CoV-2 infection, it is possible that the percentage of persons with antibody 257 concentrations meeting or exceeding those concentrations associated with 70% and 90% COVID-19 VE 258 were underestimated. However, as a result of the sharp rise in COVID-19 cases in the United States in 259 mid-June 2020 (Supplementary Figure 2) [21], >50% of cases reported in the country prior to July 27, 260 2020 (date first specimens used in this study were collected) occurred after June 15, 2020. This indicates 261 that the majority of sera in this study were likely to have been collected within 73 days of SARS-CoV-2 262 infection, a time before IgG antibody concentrations would be expected to have significantly waned 263 from peak post-infection levels [22]. 264 Second, 13.6% of persons had anti-RBD IgG concentrations below the cutoff value of the assay 265 (37.5 BAU/mL). However, the anti-RBD IgG concentration associated with 70% mRNA-1273 VE (8.0 266 BAU/mL) is below the cutoff value of the Cov2Quant IgG® Assay used in this study. Therefore, it is 267 possible that some persons below the assay cutoff value might have had anti-RBD IgG concentrations 268 greater than or equal to 8.0 BAU/mL, leading us to underestimate the percentage of persons with 269 antibody concentrations meeting or exceeding those concentrations associated with 70% mRNA-1274 270 COVID-19 VE. 271 Third, extrapolating these population-level results to individual-level clinical decision making with 272 regard to immune protection based on a single antibody test poses a challenge. The sera tested here were

273 untimed with regard to onset of infection and we have no knowledge of the immune status of the

274 individuals in terms of co-morbidities and medications. These challenges are also applicable to post-

vaccination sera in terms of certain populations responding less well to vaccines in terms of neutralizing
and binding antibodies as compared to healthy volunteers in vaccine trials and limited availability of
standardized quantitative assays [3].
Fourth, our findings, as well as the timing of the ChAdOx1 CoV-19 and mRNA-1273 VE trials,
predate the circulation of the Delta variant of SARS-CoV-2 that exhibits a decreased sensitivity to post-

280 vaccination antibody neutralization compared to the Alpha variant of the virus [23]. Therefore, our data

is not able to address potential protection of persons infected SARS-CoV-2 in mid-2020 against

282 infection with the Delta variant of the virus.

Finally, the efficiency and redundancy of the immune system, especially for the prevention of severe

disease, in terms of humoral [12], cellular immunity, memory and anamnestic response on second

285 exposure to SARS-CoV-2 likely contribute to protection beyond an estimate indicated solely by single

antibody concentrations [6, 24].

287 In conclusion, we demonstrate that in this sample, most non-vaccinated persons with qualitative

antibody evidence of prior infection had quantitative antibody concentrations against SARS-CoV-2 that

289 met or exceeded antibody levels associated with 70% VE. However, only a small proportion had

antibody responses that met or exceeded levels associated with 90% VE. Our findings suggest that

291 persons with a prior COVID-19 would benefit from vaccination to maximize protective antibody

292 concentrations against symptomatic COVID-19.

293 Notes

294	Acknowledgments. The authors thank Marla Williams, Morgan Herle, Wade Tanico, and Paul Theobald
295	from Labcorp for help received in planning and execution of sample logistics and data acquisition. A
296	special thanks goes to the reference laboratory operators that performed Cov2Quant IgG® and
297	PhenoSense® CoV Neutralizing Antibody assays. We also thank members of the Multistate Assessment
298	of SARS-CoV-2 Seroprevalence (MASS) steering group, including Lyle Peterson, Margaret Honein,
299	Adam MacNeil, Eduardo Azziz-Baumgartner, Francisco Averhoff, Sridhar Basavaraju, Tina Benoit,
300	Carla Black, Kevin Berney, Ryan Weigand, Michele Owen, Ruchi Pancholy, and Lisa Grohskopf.
301	Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily
302	represent the official position of the Centers for Disease Control and Prevention.
303	Financial support. This work was supported by the United States Centers for Disease Control and

304 Prevention, Atlanta, Georgia.

305 REFERENCES

- 306 1. US Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States.
- 307 Available at: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total.
- 308 Accessed October 14, 2021.
- 309 2. Jones JM. About One in Five Americans Remain Vaccine-Resistant. Available at:
- 310 https://news.gallup.com/poll/353081/one-five-americans-remain-vaccine-resistant.aspx. Accessed
- 311 September 12, 2021.
- 312 3. US Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 Infection-induced and
- 313 Vaccine-induced Immunity. Available at: <u>https://www.cdc.gov/coronavirus/2019-</u>
- 314 <u>ncov/science/science-briefs/vaccine-induced-immunity.html</u>. Accessed November 5, 2021 2021.
- 315 4. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in
- 316 rhesus macaques. Science **2020**; 369:812-7.
- 317 5. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus
- 318 macaques. Nature **2021**; 590:630-4.
- 319 6. Corbett KS, Nason MC, Flach B, et al. Immune correlates of protection by mRNA-1273 vaccine
- against SARS-CoV-2 in nonhuman primates. Science **2021**; 373:eabj0299.
- 321 7. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV Antibody Combination
- 322 to Prevent Covid-19. N Engl J Med **2021**; 385:1184-95.
- 8. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2
- Infection in Health Care Workers. N Engl J Med **2021**; 384:533-40.
- 325 9. Mattiuzzo G, Bentley EM, Hassall M, et al. Establishment of the WHO International Standard and
- 326 Reference Panel for anti-SARS-CoV-2 antibody (WHO/BS/2020/2403): World Health Organization,
- **2020**.

- 328 10. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate
- 329 for COVID-19 vaccines. Vaccine **2021**; 39:4423-8.
- 330 11. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic
- 331 SARS-CoV-2 infection. medRxiv 2021.
- 332 12. Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the mRNA-1273
- 333 COVID-19 Vaccine Efficacy Trial. medRxiv **2021**.
- 13. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of
- immune protection from symptomatic SARS-CoV-2 infection. Nat Med **2021**; 27:1205-11.
- 14. Gundlapalli AV, Salerno RM, Brooks JT, et al. SARS-CoV-2 Serologic Assay Needs for the Next
- 337 Phase of the US COVID-19 Pandemic Response. Open Forum Infect Dis 2021; 8:ofaa555.
- 338 15. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature
- **2020**; 584:115-9.
- 340 16. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in
- 341 convalescent individuals. Nature **2020**; 584:437-42.
- 34217. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of
- 343 September 2020. JAMA Intern Med **2021**; 181:450-60.
- 18. Markmann AJ, Giallourou N, Bhowmik DR, et al. Sex disparities and neutralizing antibody
- 345 durability to SARS-CoV-2 infection in convalescent individuals. medRxiv **2021**.
- 19. Kappelman MD, Weaver KN, Boccieri M, et al. Humoral Immune Response to Messenger RNA
- 347 COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease. Gastroenterology **2021**.
- 348 20. Jones JM, Stone M, Sulaeman H, et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2
- 349 Seroprevalence Based on Blood Donations, July 2020-May 2021. JAMA 2021.

- 350 21. US Centers for Disease Control and Prevention. Trends in Number of COVID-19 Cases and Deaths
- 351 in the US Reported to CDC, by State/Territory. Available at: <u>https://covid.cdc.gov/covid-data-</u>
- 352 <u>tracker/#trends_dailycases</u>. Accessed October 14, 2021.
- 353 22. Egbert ER, Xiao S, Colantuoni E, et al. Durability of Spike Immunoglobin G Antibodies to SARS-
- 354 CoV-2 Among Health Care Workers With Prior Infection. JAMA Netw Open **2021**; 4:e2123256.
- 355 23. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to
- antibody neutralization. Nature **2021**; 596:276-80.
- 357 24. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell **2021**; 184:861-80.

358	Figure 1. SARS-CoV-2 50% neutralizing antibody titer (NT50) concentrations and anti-SARS-CoV-2
359	receptor binding domain (RBD) IgG concentrations for the overall convenience sample of 3,067 serum
360	specimens collected during July 27,2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies
361	on a qualitative assay, and according to sex and age category. A) SARS-CoV-2 NT50 concentrations in
362	international units per mL (IU/mL) and B) Anti-SARS-CoV-2 RBD IgG concentrations in binding
363	antibody units per mL (BAU/mL). Horizontal bars represent geometric means, vertical error bars
364	represent 95% confidence intervals, and dashed horizontal lines represent assay cut-off values for
365	seropositivity. P-values from t-tests (sex) and post-hoc Tukey tests (age class) are shown for each sex
366	and age class comparison. Bolded p-values denote statistical significance (p<0.05). Dotted horizontal
367	lines represent antibody concentrations associated with 70% and 90% ChAdOx1 [11] and mRNA-1273
368	[12] vaccine efficacy (VE). The percentage of sera with antibody concentrations that meet or exceed the
369	concentrations represented by each of the horizontal dotted lines are shown below the charts.
370	Figure 2. Correlations between SARS-CoV-2 50% neutralizing antibody titer (NT ₅₀) concentrations in
371	international units per mL (IU/mL) and anti-SARS-CoV-2 receptor binding domain (RBD) IgG
372	concentrations in binding antibody units per mL (BAU/mL) for the convenience sample of 3,067 serum
373	specimens collected during July 27,2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies
374	on a qualitative assay. A) Overall, B) by sex, and C) by age class.

375 Figure 3. SARS-CoV-2 50% neutralizing antibody titer (NT₅₀) concentrations in international units per

376 mL (IU/mL) and anti-SARS-CoV-2 receptor binding domain (RBD) IgG concentrations in binding

antibody units per mL (BAU/mL) for the overall convenience sample of 3,067 serum specimens

378 collected during July 27,2020-August 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a

379 qualitative assay compared to 28 days post COVID-19 vaccination concentrations in ChAdOx1 [11] and

380 mRNA-1273 [12] VE study participants classified as not having COVID-19 during the follow-up period.

381 A) Median and interquartile range SARS-CoV-2 NT₅₀ concentrations for the overall convenience

382	sample compared to concentrations in VE study participants who received the ChAdOx1 vaccine and
383	were classified as not having COVID-19 during the follow-up period, B) Geometric mean and 95%
384	confidence interval SARS-CoV-2 NT50 concentrations for the overall convenience sample compared to
385	concentrations in VE study participants who received the mRNA-1273 vaccine and were classified as
386	not having COVID-19 during the follow-up period, C) Median and interquartile range anti-SARS-CoV-
387	2 RBD IgG concentrations for the overall convenience sample compared to concentrations in VE study
388	participants who received the ChAdOx1 vaccine and were classified as not having COVID-19 during the
389	follow-up period, and D) Geometric mean and 95% CI anti-SARS-CoV-2 RBD IgG concentrations for
390	the overall convenience sample compared to concentrations in VE study participants who received the
391	mRNA-1273 vaccine and were classified as not having COVID-19 during the follow-up period.
392	Horizontal bars represent medians or geometric means, and vertical error bars represent the interquartile

393 range surrounding the median or 95% confidence intervals surrounding the geometric mean.





